Quintara Biosciences Completes Laragen Acquisition
Quintara Biosciences has successfully finalized its acquisition of Laragen's Sanger Sequencing services, previously managed by Transnetyx. This strategic move ensures seamless continuation of services for existing customers and bolsters Quintara's footprint in California's thriving life sciences sector.
Commitment to Uninterrupted Services
All services that Laragen provided, such as DNA Sequencing, Microbial Identification, and Cell Line Identification, will remain uninterrupted. Customers can expect the same dedicated team and equipment they have relied on for years. Quintara is committed to honoring the existing pricing structures, making the transition as smooth as possible for everyone involved.
Strategic Importance of the Acquisition
Los Angeles is recognized as a vital center for innovation in biomedical research, hosting esteemed institutions like UCLA, Caltech, and City of Hope. The combination of Laragen's established market presence with Quintara's expansive capabilities will significantly enhance the company's ability to deliver high-quality life science services and meet the increasing demand in this sector.
Insights from Leadership
Daniel Wang, CEO of Quintara Biosciences, emphasized that this acquisition reflects their unwavering commitment to providing continuous services to researchers, while also expanding their strategic operational footprint. He noted, "Los Angeles serves as a critical hub linking our Bay Area and San Diego operations. Strengthening our presence here allows us to serve the entire West Coast with expedited services and an expanded range of options."
Enhancing Local Infrastructure
Sue Zhao, General Manager of Quintara Biosciences, elaborated on the operational advantages of integrating Laragen's services. The acquisition not only increases throughput but also strengthens local infrastructure for sequencing. It supports their growth into long-read and high-throughput sequencing applications, enabling Quintara to deliver comprehensive solutions that integrate traditional Sanger workflows with modern sequencing technologies.
About Quintara Biosciences
Quintara Biosciences stands out as a premier genomics and molecular biology CRO/CDMO. They provide a wide array of sequencing and molecular services tailored to the biotech and academic sectors. With operational bases in several key areas across the U.S., including Boston, San Francisco, San Diego, Los Angeles, and Houston, Quintara specializes in advanced techniques such as Sanger and NGS, alongside molecular biology solutions that facilitate rapid discovery and development.
About Transnetyx
Transnetyx is a global leader in automated genotyping solutions, committed to empowering researchers through innovative and efficient discovery tools. With headquarters in Cordova, TN, and an office in Europe, Transnetyx is dedicated to driving precision and fostering global partnerships to advance scientific research.
Frequently Asked Questions
What prompted Quintara Biosciences to acquire Laragen?
The acquisition was aimed at ensuring service continuity for customers while enhancing Quintara's strategic position in the evolving life sciences landscape.
Will existing customers experience any changes in service?
No, all existing services are set to continue without disruption, maintaining the same team and infrastructure that customers have used before.
How does this acquisition benefit researchers in Los Angeles?
The acquisition enhances service offerings and operational capacity, ensuring faster and more efficient service for researchers benefiting from Quintara’s expanded capabilities.
What overarching strategy does this acquisition fit into for Quintara?
This acquisition is part of Quintara's broader strategy to enhance its operational footprint and meet the growing demand for comprehensive life science services across the West Coast.
What other services does Quintara provide beyond Sanger sequencing?
Quintara provides a range of molecular biology and sequencing services, including NGS, Nanopore technologies, and recombinant antibody/protein production to support diverse research needs.
